• Company
• Keytruda reimb. not deliberated in November PBAC meeting
• by Eo, Yun-Ho Nov 12, 2021 10:23am

• Company
• Hanmi Pharmaceutical's first technology export in a year
• by Chon, Seung-Hyun Nov 12, 2021 05:56am

• Policy
• More convenient new dementia treatments introduced to market
• by Lee, Tak-Sun Nov 12, 2021 05:54am

• GI innovation·Merck signed MOU to develop new drugs
• by Nho, Byung Chul Nov 12, 2021 05:54am

• Company
• GX-17, aimed at treating COVID-19, resumes clinical trials
• by Kim, Jin-Gu Nov 12, 2021 05:54am

• Company
• Will BMS's 'Revlimid' be reimbursed as RVd therapy?
• by Eo, Yun-Ho Nov 11, 2021 06:01am

• Product
• Claiming a more expensive drug than a generic
• by Kim JiEun Nov 11, 2021 06:00am

• Policy
• Controversy rise over standards used in pricing negotiations
• by Moon, sung-ho Nov 11, 2021 06:00am

• Company
• What do scholars refer to as effective tx for myeloma?
• by Nov 11, 2021 06:00am

• Policy
• RWD & RWE will be important means of use in post-evaluation
• by Kim, Jung-Ju Nov 11, 2021 06:00am